日本藥物基因體學市場報告（按技術、應用、最終用戶和地區分類，2026-2034年）

Japan Pharmacogenomics Market Report by Technology, Application, End User, and Region 2026-2034

出版日期: 2026年01月01日 | 出版商:

IMARC | 英文 121 Pages | 商品交期: 5-7個工作天內

價格

簡介目錄

2025年，日本藥物基因體學市場規模達4.015億美元。展望未來， IMARC Group預計到2034年，該市場規模將達到6.835億美元，2026年至2034年期間的複合年成長率（CAGR）為6.09%。醫療基礎設施的不斷完善、人口老化加劇、領先企業持續開展研發活動以及政府機構和醫療組織日益重視的教育舉措，都是推動市場成長的關鍵因素。

本報告解答的關鍵問題：

日本藥物基因體學市場目前的表現如何？未來幾年又將如何發展？
新冠疫情對日本藥物基因體學市場產生了哪些影響？
日本藥物基因體學市場依技術分類的組成是怎樣的？
日本藥物基因體學市場按應用領域分類的組成是怎樣的？
日本藥物基因體學市場以最終用戶分類的組成是怎樣的？
日本藥物基因體學市場價值鏈的各個階段有哪些？
日本藥物基因體學的關鍵促進因素和挑戰是什麼？
日本藥物基因體學市場的結構是怎麼樣的？主要參與者有哪些？
日本藥物基因體學市場的競爭程度如何？

Japan pharmacogenomics market size reached USD 401.5 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 683.5 Million by 2034, exhibiting a growth rate (CAGR) of 6.09% during 2026-2034. The expanding healthcare infrastructure, increasing aging population, continual research, and development (R&D) activities by leading players, and rising educational initiatives by government bodies and healthcare organizations represent some of the key factors driving the market.

Pharmacogenomics is the study of how genes influence an individual's response to medications. This scientific discipline combines elements of pharmacology, which is the science of drugs, and genomics, which is the study of genes and their functions. The primary aim of pharmacogenomics is to optimize drug therapy, maximizing effectiveness while minimizing adverse effects. Pharmacogenomics allows for a more personalized approach to medicine. It allows for tailored medical therapy based on an individual's genetic makeup. This means that treatments can be specifically designed to work best for each person, enhancing effectiveness. Personalized treatment can reduce the financial burden on the healthcare system. Fewer trials and errors in prescribing medication mean that patients can potentially reach an effective treatment faster, reducing hospital stays and lowering overall healthcare costs. Pharmacogenomics can also benefit pharmaceutical companies by identifying new drug targets and assisting in the development of medication that is more effective and safer, which can lead to faster regulatory approval.

Japan Pharmacogenomics Market Trends:

The country's robust healthcare infrastructure, characterized by cutting-edge technology and advanced research facilities, is driving the market in Japan. Japan's reputation as a leader in the field of technology and medicine facilitates a supportive environment for the growth of pharmacogenomics, with significant investments in research and development. Moreover, the strong government support for genomics research is supporting the market. Regulatory policies and funding are geared towards encouraging innovations in personalized medicine, including pharmacogenomics. The Japanese government has launched several initiatives to accelerate research in genomics and its application in medical treatments, thereby creating a favorable ecosystem for the pharmacogenomics market to flourish. The aging population in Japan also plays a critical role in augmenting the market. Older individuals are more likely to have complex healthcare needs and multiple medications, making them ideal candidates for personalized treatment plans. Pharmacogenomics can offer optimized drug therapies that are both effective and safe for this demographic, reducing adverse drug reactions, which are a leading cause of hospitalization among the elderly. In addition, Japan has a relatively high incidence of certain diseases that can benefit from pharmacogenomic applications, including various types of cancer and cardiovascular disorders. The ability to tailor treatments for these prevalent conditions can improve outcomes and reduce healthcare costs, making pharmacogenomics an attractive option for both healthcare providers and patients. Furthermore, the market is fueled by increasing public awareness about the benefits of personalized medicine. Besides, educational initiatives by government bodies and healthcare organizations have also contributed to a greater understanding of the advantages of pharmacogenomics, thus encouraging more people to opt for such tests and treatments.

Japan Pharmacogenomics Market Segmentation:

Technology Insight

Polymerase Chain Reaction
Microarray
DNA Sequencing
Mass Spectrometry
Electrophoresis
Others

Application Insights:

Oncology
Infectious Diseases
Cardiovascular Diseases
Neurological Diseases
Psychiatry
Pain Management
Others

End User Insights:

Hospitals and Clinics
Academic and Research Institutes

Regional Insights:

Kanto Region
Kansai/Kinki Region
Central/ Chubu Region
Kyushu-Okinawa Region
Tohoku Region
Chugoku Region
Hokkaido Region
Shikoku Region
The report has also provided a comprehensive analysis of all the major regional markets, which include Kanto Region, Kansai/Kinki Region, Central/ Chubu Region, Kyushu-Okinawa Region, Tohoku Region, Chugoku Region, Hokkaido Region, and Shikoku Region.

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

How has the Japan pharmacogenomics market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the Japan pharmacogenomics market?
What is the breakup of the Japan pharmacogenomics market on the basis of technology?
What is the breakup of the Japan pharmacogenomics market on the basis of application?
What is the breakup of the Japan pharmacogenomics market on the basis of end user?
What are the various stages in the value chain of the Japan pharmacogenomics market?
What are the key driving factors and challenges in the Japan pharmacogenomics?
What is the structure of the Japan pharmacogenomics market and who are the key players?
What is the degree of competition in the Japan pharmacogenomics market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pharmacogenomics Market - Introduction

4.1 Overview
4.2 Market Dynamics
4.3 Industry Trends
4.4 Competitive Intelligence

5 Japan Pharmacogenomics Market Landscape

5.1 Historical and Current Market Trends (2020-2025)
5.2 Market Forecast (2026-2034)

6 Japan Pharmacogenomics Market - Breakup by Technology

6.1 Polymerase Chain Reaction
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2020-2025)
- 6.1.3 Market Forecast (2026-2034)
6.2 Microarray
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2020-2025)
- 6.2.3 Market Forecast (2026-2034)
6.3 DNA Sequencing
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2020-2025)
- 6.3.3 Market Forecast (2026-2034)
6.4 Mass Spectrometry
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2020-2025)
- 6.4.3 Market Forecast (2026-2034)
6.5 Electrophoresis
- 6.5.1 Overview
- 6.5.2 Historical and Current Market Trends (2020-2025)
- 6.5.3 Market Forecast (2026-2034)
6.6 Others
- 6.6.1 Historical and Current Market Trends (2020-2025)
- 6.6.2 Market Forecast (2026-2034)

7 Japan Pharmacogenomics Market - Breakup by Application

7.1 Oncology
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2020-2025)
- 7.1.3 Market Forecast (2026-2034)
7.2 Infectious Diseases
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2020-2025)
- 7.2.3 Market Forecast (2026-2034)
7.3 Cardiovascular Diseases
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2020-2025)
- 7.3.3 Market Forecast (2026-2034)
7.4 Neurological Diseases
- 7.4.1 Overview
- 7.4.2 Historical and Current Market Trends (2020-2025)
- 7.4.3 Market Forecast (2026-2034)
7.5 Psychiatry
- 7.5.1 Overview
- 7.5.2 Historical and Current Market Trends (2020-2025)
- 7.5.3 Market Forecast (2026-2034)
7.6 Pain Management
- 7.6.1 Overview
- 7.6.2 Historical and Current Market Trends (2020-2025)
- 7.6.3 Market Forecast (2026-2034)
7.7 Others
- 7.7.1 Historical and Current Market Trends (2020-2025)
- 7.7.2 Market Forecast (2026-2034)

8 Japan Pharmacogenomics Market - Breakup by End User

8.1 Hospitals and Clinics
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2020-2025)
- 8.1.3 Market Forecast (2026-2034)
8.2 Academic and Research Institutes
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2020-2025)
- 8.2.3 Market Forecast (2026-2034)

9 Japan Pharmacogenomics Market - Breakup by Region

9.1 Kanto Region
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2020-2025)
- 9.1.3 Market Breakup by Technology
- 9.1.4 Market Breakup by Application
- 9.1.5 Market Breakup by End User
- 9.1.6 Key Players
- 9.1.7 Market Forecast (2026-2034)
9.2 Kansai/Kinki Region
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2020-2025)
- 9.2.3 Market Breakup by Technology
- 9.2.4 Market Breakup by Application
- 9.2.5 Market Breakup by End User
- 9.2.6 Key Players
- 9.2.7 Market Forecast (2026-2034)
9.3 Central/ Chubu Region
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2020-2025)
- 9.3.3 Market Breakup by Technology
- 9.3.4 Market Breakup by Application
- 9.3.5 Market Breakup by End User
- 9.3.6 Key Players
- 9.3.7 Market Forecast (2026-2034)
9.4 Kyushu-Okinawa Region
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2020-2025)
- 9.4.3 Market Breakup by Technology
- 9.4.4 Market Breakup by Application
- 9.4.5 Market Breakup by End User
- 9.4.6 Key Players
- 9.4.7 Market Forecast (2026-2034)
9.5 Tohoku Region
- 9.5.1 Overview
- 9.5.2 Historical and Current Market Trends (2020-2025)
- 9.5.3 Market Breakup by Technology
- 9.5.4 Market Breakup by Application
- 9.5.5 Market Breakup by End User
- 9.5.6 Key Players
- 9.5.7 Market Forecast (2026-2034)
9.6 Chugoku Region
- 9.6.1 Overview
- 9.6.2 Historical and Current Market Trends (2020-2025)
- 9.6.3 Market Breakup by Technology
- 9.6.4 Market Breakup by Application
- 9.6.5 Market Breakup by End User
- 9.6.6 Key Players
- 9.6.7 Market Forecast (2026-2034)
9.7 Hokkaido Region
- 9.7.1 Overview
- 9.7.2 Historical and Current Market Trends (2020-2025)
- 9.7.3 Market Breakup by Technology
- 9.7.4 Market Breakup by Application
- 9.7.5 Market Breakup by End User
- 9.7.6 Key Players
- 9.7.7 Market Forecast (2026-2034)
9.8 Shikoku Region
- 9.8.1 Overview
- 9.8.2 Historical and Current Market Trends (2020-2025)
- 9.8.3 Market Breakup by Technology
- 9.8.4 Market Breakup by Application
- 9.8.5 Market Breakup by End User
- 9.8.6 Key Players
- 9.8.7 Market Forecast (2026-2034)

10 Japan Pharmacogenomics Market - Competitive Landscape

10.1 Overview
10.2 Market Structure
10.3 Market Player Positioning
10.4 Top Winning Strategies
10.5 Competitive Dashboard
10.6 Company Evaluation Quadrant

11 Profiles of Key Players

11.1 Company A
- 11.1.1 Business Overview
- 11.1.2 Product Portfolio
- 11.1.3 Business Strategies
- 11.1.4 SWOT Analysis
- 11.1.5 Major News and Events
11.2 Company B
- 11.2.1 Business Overview
- 11.2.2 Product Portfolio
- 11.2.3 Business Strategies
- 11.2.4 SWOT Analysis
- 11.2.5 Major News and Events
11.3 Company C
- 11.3.1 Business Overview
- 11.3.2 Product Portfolio
- 11.3.3 Business Strategies
- 11.3.4 SWOT Analysis
- 11.3.5 Major News and Events
11.4 Company D
- 11.4.1 Business Overview
- 11.4.2 Product Portfolio
- 11.4.3 Business Strategies
- 11.4.4 SWOT Analysis
- 11.4.5 Major News and Events
11.5 Company E
- 11.5.1 Business Overview
- 11.5.2 Product Portfolio
- 11.5.3 Business Strategies
- 11.5.4 SWOT Analysis
- 11.5.5 Major News and Events

12 Japan Pharmacogenomics Market - Industry Analysis

12.1 Drivers, Restraints, and Opportunities
- 12.1.1 Overview
- 12.1.2 Drivers
- 12.1.3 Restraints
- 12.1.4 Opportunities
12.2 Porters Five Forces Analysis
- 12.2.1 Overview
- 12.2.2 Bargaining Power of Buyers
- 12.2.3 Bargaining Power of Suppliers
- 12.2.4 Degree of Competition
- 12.2.5 Threat of New Entrants
- 12.2.6 Threat of Substitutes
12.3 Value Chain Analysis